Related Experiment Video
Updated: May 20, 2026
10:13
Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
Published on: July 31, 2017
[Current conceptions of neurocytoprotective therapy]
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|July 17, 2012
Summary
Cerebrolysin, an established neuroprotective drug, shows significant clinical effectiveness. Its efficacy in treating brain ischemia, Alzheimer's disease, and cognitive disorders is supported by extensive research and clinical trials.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Cerebrolysin is a long-standing neuroprotective agent.
- Understanding its pharmacological effects and clinical utility is crucial for neurological disorder management.
Purpose of the Study:
- To review the pharmacological effects and clinical effectiveness of Cerebrolysin.
- To detail the molecular mechanisms and clinical trial outcomes of Cerebrolysin.
Main Methods:
- Review of experimental data on molecular mechanisms.
- Analysis of clinical trials in various neurological conditions.
Main Results:
- Cerebrolysin demonstrates neuroprotective properties.
- Clinical trials confirm efficacy in acute and chronic brain ischemia, Alzheimer's disease, and cognitive impairments.
Conclusions:
- Cerebrolysin's effectiveness is substantiated by fundamental research, including animal models and cell cultures.
- Multiple clinical trials support Cerebrolysin's use in diverse patient pathologies.
